To synthesize current literature on the pathogenesis and clinical impact of antibody-mediated rejection (ABMR) and post-transplant metabolic syndromes, and to explore emerging diagnostic tools and therapeutic strategies.
Key Findings:
ABMR is a leading cause of late graft failure in kidney transplantation.
30% to 50% of kidney transplant recipients develop metabolic syndromes within the first year.
Metabolic abnormalities can exacerbate ABMR through enhanced endothelial activation and inflammation.
Intensified immunosuppression to treat ABMR can worsen metabolic profiles, creating a vicious cycle.
Novel therapeutic agents show promise but lack long-term efficacy data.
Interpretation:
Integrated immunometabolic strategies are crucial for improving graft and patient survival, highlighting the need for personalized approaches in immunosuppression and metabolic health management.
Limitations:
Limited data on long-term efficacy of emerging therapeutic agents.
Need for more research to personalize immunosuppression and target metabolic health.
Conclusion:
Future research should focus on breaking the feedback loop between ABMR and metabolic disease to enhance outcomes in kidney transplantation.
